Trade Names:Ansaid- Tablets 50 mg- Tablets 100 mgApo-Flurbiprofen (Canada)Flurbiprofen Sodium
Trade Names:Ocufen- Ophthalmic solution 0.03%
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
T max is about 2 h (range, 1.2 to 2.3 h).
Flurbiprofen is more than 99% protein bound. Vd is 0.12 L/kg.
The major metabolite is 4′-hydroxy-flurbiprofen.
The t ½ is about 4.7 to 5.7 h. Less than 3% of flurbiprofen is excreted unchanged in the urine; 70% of the dose is eliminated in the urine as parent drug and metabolites.
Elimination of flurbiprofen metabolites may be reduced; dose reduction may be necessary to prevent accumulation of flurbiprofen metabolites.Hepatic Function Impairment
Hepatic metabolism may account for 90% or more of flurbiprofen elimination; protein binding may be decreased in patients with liver disease and serum albumin concentrations less than 3.1 g/dL.
Treatment of rheumatoid arthritis and osteoarthritis.Ophthalmic
Inhibition of intraoperative miosis.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; treatment of perioperative pain in the setting of coronary artery bypass graft surgery (PO only); hypersensitivity to any component of the product.
PO Starting dosage is 200 to 300 mg in divided doses 2 to 4 times daily. The largest recommended single dose in a multiple-dose regimen is 100 mg. Adjust dose and frequency per patient needs.Inhibition of Intraoperative MiosisAdults
Topical 1 drop of 0.03% solution every 30 min beginning 2 h before surgery (4 drops total).
Store tablets and ophthalmic solution at controlled room temperature (68° to 77°F).
Plasma aminoglycoside levels may be elevated.Angiotensin-converting enzyme (ACE) inhibitors
NSAIDs may decrease the antihypertensive effect of ACE inhibitors.Beta-blockers
Decreased antihypertensive effect of beta-blocker.Cimetidine
May increase AUC of flurbiprofen.Diuretics
Decreased diuretic effect.Lithium
Increased lithium levels and toxicity.Methotrexate
Increased methotrexate levels and toxicity.Salicylates
Increased risk of GI toxicity; may reduce flurbiprofen concentrations 50%. Coadministration is not recommended.SSRIs (eg, fluoxetine, paroxetine)
The risk of GI adverse reactions may be increased.Warfarin
Increased risk of gastric erosion and bleeding.
May prolong bleeding time.
Amnesia, anxiety, asthenia, depression, dizziness/vertigo, headache, increased reflexes, insomnia, malaise, nervousness, somnolence, tremor (at least 1%).
Rash (at least 1%).
Rhinitis, tinnitus, vision changes (at least 1%); fibrosis, increased bleeding tendency of ocular tissues in conjunction with ocular surgery, miosis, mydriasis, ocular irritation, transient burning and stinging upon instillation (ophthalmic use).
Abdominal pain, constipation, diarrhea, dyspepsia/heartburn, flatulence, GI bleeding, nausea, vomiting (at least 1%).
UTI (at least 1%).
Body weight changes (at least 1%).
Edema (at least 1%).
NSAIDs may cause an increased risk of serious CV thrombotic events, MI, and stroke, which can be fatal. This risk may increase with length of therapy. Patients with CV disease or risk factors for CV disease may be at greater risk. NSAIDs cause an increased risk of serious GI adverse reactions, including bleeding, ulceration, inflammation, and perforation of the stomach or intestines, which can be fatal. These reactions can occur any time during use and without warning symptoms. Elderly patients are at greater risk of serious GI reactions.
Carefully monitor patients who may be adversely affected by alterations in platelet function (eg, patients with coagulation disorders or receiving anticoagulant therapy). Check CBC and chemistry profile periodically. Follow chronically treated patients for signs and symptoms of GI tract ulceration and bleeding. Monitor LFTs, Hct, and Hgb periodically during long-term therapy. Monitor renal function and patient status carefully in patients with renal function impairment. Perform eye examination if patient experiences visual disturbances.
Category C . Avoid in late pregnancy.
Excreted in breast milk (tablets); undetermined (ophthalmic).
Safety and efficacy not established.
Use with caution.
May occur; do not use in aspirin-sensitive individuals because of possible cross-sensitivity.
Use is not recommended in patients with advanced kidney disease. Long-term treatment with NSAIDs may result in renal papillary necrosis and other renal injury.
Use with caution.
Use with caution in patients with fluid retention, hypertension, or heart failure.
May cause drowsiness or dizziness.
Do not administer to patients with aspirin triad, which typically occurs in patients with asthma who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs.
Patients with asthma may have aspirin-sensitive asthma, which may be associated with severe and sometimes fatal bronchospasm. Do not administer flurbiprofen to patients with this type of aspirin-sensitivity because of possible cross-reactivity.
May inhibit platelet aggregation. Use with caution in patients with known bleeding tendencies or who are receiving other medications that may prolong bleeding time.
Use with caution. Rehydrate patient before instituting therapy.
Anemia may occur with NSAID use.
New hypertension or worsening of preexisting hypertension, either of which may contribute to increased risk of CV events, may occur.
Has been observed. Use with caution in patients with hypertension or compromised cardiac function.
NSAIDs inhibit platelet aggregation and have been reported to prolong bleeding time.
Serious and sometimes fatal skin adverse reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur.
Blurred and/or diminished vision may occur.
Acute renal failure, coma, drowsiness, epigastric pain, GI bleeding, hypertension, lethargy, nausea, respiratory depression, vomiting.
Copyright © 2009 Wolters Kluwer Health.